IMRAS—Immunization with radiation-attenuated Plasmodium falciparum sporozoites by mosquito bite: Cellular immunity to sporozoites, CSP, AMA1, TRAP and CelTOS

• Published in: PloS one Vol. 16; no. 8; p. e0256396
• Main Authors: Sedegah, Martha, Hollingdale, Michael R., Ganeshan, Harini, Belmonte, Maria, Huang, Jun, Belmonte, Arnel, Inoue, Sandra, Velasco, Rachel, Hickey, Bradley, Teneza-Mora, Nimfa, Lumsden, Joanne, Reyes, Sharina, Banania, Jo Glenna, Reyes, Anatalio, Guzman, Ivelese, Richie, Thomas L., Epstein, Judith E., Villasante, Eileen
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 20.08.2021; Public Library of Science (PLoS)
• Subjects: Adolescent; Adult; Analysis; Animals; Antigens; Antigens, Protozoan - immunology; Biology and Life Sciences; Culicidae - immunology; Culicidae - parasitology; Female; Health aspects; Humans; Immunity, Cellular; Immunization; Immunization - methods; Insect Bites and Stings - immunology; Interferon-gamma - immunology; Interferon-gamma - metabolism; Interleukin-2 - immunology; Malaria Vaccines - immunology; Malaria, Falciparum - immunology; Malaria, Falciparum - parasitology; Malaria, Falciparum - prevention & control; Male; Medicine and Health Sciences; Middle Aged; Plasmodium falciparum; Plasmodium falciparum - immunology; Plasmodium falciparum - radiation effects; Protozoan Proteins - immunology; Research and Analysis Methods; Sporozoites - immunology; Sporozoites - radiation effects; Vaccines, Attenuated - immunology; Young Adult; United States
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0256396

Immunization with radiation-attenuated sporozoites (RAS) by mosquito bites provides >90% sterile protection against Plasmodium falciparum malaria in humans. We conducted a clinical trial based on data from previous RAS clinical trials that suggested that 800-1200 infected bites should induce ~50% protective vaccine efficacy (VE) against controlled human malaria infection (CHMI) administered three weeks after the final immunization. Two cohorts were immunized separately. VE was 55% in Cohort 1 but 90% in Cohort 2, the cohort that received a higher first dose and a reduced (fractional) fifth dose. Immune responses were better boosted by the fractional fifth dose in Cohort 2 and suggested the importance of the fractional fifth dose for increased protection in Cohort 2 responses. Three protected subjects were later boosted and were protected suggesting that protection could be extended to at least 67 weeks. The ex vivo FluoroSpot assay was used to measure peripheral IFN-γ, IL2, and IFN-γ+IL2 responses to PfNF54 sporozoites and malaria antigens CSP, AMA1, TRAP, and CelTOS using pools of synthetic overlapping 15mer peptides spanning each antigen. There was no correlation between IFN-γ, IL2, and IFN-γ+IL2 responses to sporozoites and protection, but fold-increases between post-4th and post-5th responses greater than 1.0 occurred mostly in protected subjects. IFN-γ and IL2 responses to TRAP, CelTOS and CSP occurred only in protected subjects. Peripheral IFN-γ, IL2, and IFN-γ+IL2 responses were short-lived and low by 27 weeks post-CHMI but were restored by boosting. These studies highlight the importance of vaccine dose and schedule for vaccine efficacy, and suggest that CSP, TRAP, AMA1 and CelTOS may be targets of protective immunity. The correlation between fold-increases in responses and protection should be explored in other vaccine trials. ClinicalTrials.gov NCT01994525.